drugset / Trial / NCT01259518
Dose Escalation Study of TriN2755 in Advanced Solid Tumors and Sarcomas
Phase 1
Unknown
48 enrolled
Trin Therapeutics GmbH
Assign Data Management and Biostatistics GmbH · collabCentral European Society for Anticancer Drug Research · collabUniversity Hospital, Essen · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is an open-label, parallel-group, two-center, safety, activity and pharmacokinetic study of TriN 2755 given at increasing dose levels as intravenous infusions administered over 4 hours. The study is divided into two parts: Part I a dose escalation phase and Part II an extension phase.
Timeline
- Start
- 2009-11
- Primary completion
- 2011-09
- Completion
- 2012-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TRIN2755 | Small molecule | 25 mg | Intravenous |
| Subject | TRIN2755 | Small molecule | 800 mg | Intravenous |